Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US-2016194335-A1 · Jul 7, 2016 · US
US10689399B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10689399-B2 |
| Application number | US-201816017371-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 25, 2018 |
| Priority date | Dec 21, 2012 |
| Publication date | Jun 23, 2020 |
| Grant date | Jun 23, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R 1 , X, W, Y 1 , Y 2 , Z 1 , and Z 4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Opening claim text (preview).
What is claimed is: 1. A compound having Formula (I): or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is phenyl, substituted with one, two, or three halogens; Y 1 is hydrogen, C 1-3 alkyl or C 1-3 haloalkyl; Y 2 is hydrogen, C 1-3 alkyl or C 1-3 haloalkyl; X is —O—; W is —CHZ 2 —; Z 1 and Z 2 , taken together, form -L-; Z 4 is —CH 2 —; L is —C(R a ) 2 —C(R a ) 2 —C(R a ) 2 —; and each R a is independently hydrogen, halogen, hydroxy or C 1-4 alkyl. 2. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Y 1 is hydrogen; and Y 2 is hydrogen. 3. The compound of claim 1 , wherein the compound is selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 4. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
Ortho-condensed systems · CPC title
for HIV · CPC title
ortho- or peri-condensed with heterocyclic ring systems · CPC title
Ortho-condensed systems · CPC title
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.